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Abstract
The clinical use of several first generation HIV protease inhibitors (PIs) is associated with the development of insulin
resistance. Indinavir has been shown to act as a potent reversible noncompetitive inhibitor of zero-trans glucose influx via
direct interaction with the insulin responsive facilitative glucose transporter GLUT4. Newer drugs within this class have
differing effects on insulin sensitivity in treated patients. GLUTs are known to contain two distinct glucose-binding sites that
are located on opposite sides of the lipid bilayer. To determine whether interference with the cytoplasmic glucose binding
site is responsible for differential effects of PIs on glucose transport, intact intracellular membrane vesicles containing GLUT1
and GLUT4, which have an inverted transporter orientation relative to the plasma membrane, were isolated from 3T3-L1
adipocytes. The binding of biotinylated ATB-BMPA, a membrane impermeable bis-mannose containing photolabel, was
determined in the presence of indinavir, ritonavir, atazanavir, tipranavir, and cytochalasin b. Zero-trans 2-deoxyglucose
transport was measured in both 3T3-L1 fibroblasts and primary rat adipocytes acutely exposed to these compounds. PI
inhibition of glucose transport correlated strongly with the PI inhibition of ATB-BMPA/transporter binding. At
therapeutically relevant concentrations, ritonavir was not selective for GLUT4 over GLUT1. Indinavir was found to act as
a competitive inhibitor of the cytoplasmic glucose binding site of GLUT4 with a KI of 8.2 mM. These data establish
biotinylated ATB-BMPA as an effective probe to quantify accessibility of the endofacial glucose-binding site in GLUTs and
reveal that the ability of PIs to block this site differs among drugs within this class. This provides mechanistic insight into the
basis for the clinical variation in drug-related metabolic toxicity.
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Introduction
The development and clinical use of HIV protease inhibitors
has greatly contributed to the transition of HIV infection from a
once fatal disease to its current status as a chronic condition [1].
Tempering enthusiasm for this major advance in HIV treatment is
the growing realization that patients treated with combined
antiretroviral treatment regimens are at increased risk for the
development of pro-atherogenic metabolic side effects including
dyslipidemia and insulin resistance [2,3]. A direct contribution of
HIV protease inhibitors to altered glucose homeostasis has been
established from several clinical studies [4]. Despite growing
awareness of these treatment-related side effects, understanding
the mechanisms leading to the development of insulin resistance in
treated HIV infection remains incomplete [5]. The ability of PIs to
induce insulin resistance in treated patients is not shared by all
agents within this drug class. Indinavir and ritonavir appear to
have the greatest effect on glucose transport both in vitro and in vivo
whereas newer PIs such atazanavir and tipranavir have minimal to
no effect on insulin sensitivity [6,7]. A direct correlation between
the ability of these drugs to block glucose transport in vivo and
effects on insulin sensitivity in treated patients has been established
[8]. Due in part to toxicities and development of viral resistance
with existing PIs, the development of safer and more effective
antiviral agents remains a high priority. Detailed knowledge of the
structural basis of the adverse effects on insulin sensitivity would
greatly facilitate these efforts. Greater understanding of the
isoform selectivity of these agents would also expand their utility
in assessing the contribution of individual transporter isoforms to
general glucose homeostasis in both health and disease [9,10,11].
Insight into the molecular basis for PI-mediated insulin resistance
may also provide a basis for novel approaches to treating the
growing worldwide epidemic of type 2 diabetes mellitus.
Previous work has identified the insulin-responsive facilitative
glucose transporter GLUT4 as a direct molecular target of several
first generation HIV protease inhibitors [12]. While the molecular
mechanism by which these drugs acutely and reversibly block
GLUT4 intrinsic activity is unknown, the peptidomimetic
character found within most PIs has been shown to contribute
to this effect [13].
Although the structure of glucose transporters has been inferred
by a number of mutagenesis and labeling studies since GLUT1
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e25237was first cloned over 25 years ago, to date no crystal structure is
available for any of the GLUTs. The proteins are predicted to
contain 12 transmembrane spanning alpha helices with both the
amino and carboxy termini within the cytoplasm [14]. Extensive
kinetic analysis of GLUT1-mediated glucose transport in the
erythrocyte membrane has established the presence of two distinct
glucose binding sites on either side of the lipid bilayer which
cannot be simultaneously occupied [15]. Thus, while zero-trans
inhibition experiments have shown that indinavir acts as a non-
competitive inhibitor of GLUT4, it remains possible that
inhibition is competitive at the cytoplasmic glucose binding site.
We have hypothesized that differences in the hydrophobicity of
PIs may in part account for differences in the ability of these drugs
to inhibit GLUT4 by influencing their ability to access the
cytoplasmic surface of the transporter [13].
In order to investigate the ability of PIs to interact with the
cytoplasmic surface of GLUT1 and GLUT4, a novel photolabel-
ing-based assay has been developed which allows direct assessment
of the influence of drug-protein interactions on the accessibility of
the endofacial glucose binding site. In addition to elucidating the
mechanism by which PIs inhibit facilitative glucose transport,
these data provide a novel means to test for additional protein-
protein interactions that may influence glucose homeostasis
independent of HIV treatment.
Materials and Methods
Materials
2-Deoxyglucose (2-DOG)-1-[
3H]-glucose was purchased from
Sigma (St. Louis, MO). Crixivan (indinavir) was obtained from
Merck (White-house City, NJ). Reyataz (atazanavir) was obtained
from Bristol-Myers Squibb (Princeton, NJ). Norvir (ritonavir) was
obtained from Abbott (Chicago, IL). Tipranavir was obtained
from the U.S. National Institutes of Health (NIH) AIDS reference
and reagents program. Indinavir and atazanavir were dissolved
in water. Ritonavir and tipranavir were dissolved in ethanol. 3T3-
L1 fibroblasts were acquired from the American Type Culture
Collection. N-[2-[2-[2-[(N-Biotinyl-caproylamino)-ethoxyl]-4-[2-
(trifluoromethyl)-3H-diazirin-3-yl]benzoyl]-1,3-bis(mannopyrano-
syl-4-yloxy)-2-propylamine (PEG-biotincap-ATB-BMPA) was pur-
chased from Toronto Research Chemicals, Inc (Ontario, Canada).
GLUT1 polyclonal antibody directed against the carboxyl terminus
was a kind gift of Mike Mueckler (Washington University, St. Louis,
MO). GLUT4 antibody was custom produced by Invitrogen
(Carlsbad, CA) using a peptide corresponding to the 16 carboxy
terminal residues of GLUT4.
2-Deoxyglucose uptake measurements in 3T3-L1
fibroblasts
3T3-L1 fibroblasts were grown to confluency in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% calf
serum. The uptake of [
3H]2-Deoxyglucose (50 mM) was measured
in Krebs-Ringer phosphate buffer for 6 min at 37uC as previously
described [16]. HIV protease inhibitors were added 6 min prior to
the start of the reaction. Non-specific uptake measured in the
presence of 20 mM cytochalasin B (Sigma) was subtracted from the
experimental values.
2-Deoxyglucose uptake measurements in primary rat
adipocytes
Adipocytes from epididymal fat pads were prepared from male
Wistar rats weighing 150 – 200 g (from Charles River Labora-
tories, Inc., Wilmington, MA) as previously described [17].
Adipocytes were stimulated with 1 mM insulin for 30 min at
37uC prior to use. 2-Deoxyglucose uptakes were performed by
adding 80 ml of the cell suspension to 80 ml of Krebs-Ringer
bicarbonate Hepes buffer (KRB) (120 mM NaCl, 4 mM
KH2PO4, 1 mM MgSO4, 1 mM CaCl2, 10 mM NaHCO3, 200
nM adenosine, 30 mM Hepes, pH 7.4) containing 3% bovine
serum albumin. HIV protease inhibitors / vehicle were added
5 min prior to the initiation of the reaction. Uptakes were initiated
with the addition of 20 mlo f[
3H]2-deoxyglucose (final 2-
deoxyglucose concentration 50 mM; 0.5 mCi/assay). After 1 min
at 37
oC, reactions were quenched with cytochalasin B to a final
concentration of 0.4 mM. The cells were separated by spinning
the reaction through dinonylphthalate as previously described [17]
and the intracellular radioactivity was quantified by liquid
scintillation counting. Non-specific uptake measured in the
presence of 20 mM cytochalasin B (Sigma) was subtracted from
the experimental values.
Isolation of low-density microsomes from 3T3-L1
adipocytes
3T3-L1 fibroblasts were grown to confluency and 48 h later
subjected to differentiation as previously described [16]. 3T3-L1
adipocytes were used 10 – 14 days after differentiation. Six culture
dishes (15 cm) of adipocytes were serum-starved overnight,
washed 3 times with ice-cold HES buffer (50 mM Hepes,
pH 7.4, 255 mM sucrose, and 1 mM EDTA) containing Roche
complete protease inhibitors (Roche Applied Science, Mannheim,
Germany), scraped into 5 ml of the same buffer, and then
homogenized with either a ball-bearing homogenizer or with a
Potter-Elvehjem tissue grinder and a PTFE pestle. The low-density
microsome (LDM) fraction was obtained by differential centrifu-
gation as described previously [18]. LDM were resuspended in
phosphate buffer (25 mM phosphate, pH 7.4, 100 mM NaCl, 5%
glycerol) containing complete Roche protease inhibitors.
ATB-BMPA photolabeling of LDM
Inhibitors were added to LDM (200 mg protein unless otherwise
stated) for 10 min at room temperature. Samples (final volume
110 ml) were then incubated for 10 min at room temperature in
the dark with biotinylated ATB-BMPA (50 mM final concentra-
tion) and then placed on ice prior to UV irradiation. Reactions
were transferred to a 24-well low protein retention culture dish
(Costar, Corning, NY) and then irradiated at room temperature
5 cm from a Green Spot UV lamp for 1 min (30 sec of light,
followed by 30 sec of darkness, followed by 30 sec of light).
Isolation and quantification of biotinylated GLUT4 and
GLUT1 proteins
20 ml of BSA (1.5 mg/ml final concentration) was added to the
UV irradiated samples in a siliconized eppendorph tube. Excess
biotinylated ATB-BMPA label was removed using a 0.5 ml Zeba
Spin Desalting Column (Pierce). Biotinylated proteins were
isolated essentially as described previously [19]. Membranes were
solubilized for 30 min at 4uC with 2% Thesit detergent buffer
containing protease inhibitors. After centrifugation at 16,000 x g
for 10 min, the supernatants were incubated overnight at 4uC with
50 ml of high capacity Streptavidin Agarose resin (Pierce).
Precipitates were washed 3 times with 1% Thesit detergent buffer,
twice with 0.1% Thesit detergent buffer, and once with phosphate
buffer. Biotinylated proteins were eluted at 95 – 100uC for 20 min
in 60 ml of 2X Laemmli Sample Buffer containing 40 mM
dithiothreitol. Half of the eluted proteins were subjected to SDS-
PAGE and transferred to nitrocellulose. Immunoblot analysis was
carried out using GLUT4 and GLUT1 specific antibodies and
HIV Protease Inhibitor Binding to GLUTs
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Biosciences, Lincoln, NE).
Kinetic analysis of PI effects on ATB-BMPA labeling of
LDM
Indinavir (Ind) was added to 50 mg of LDM for 10 min at room
temperature. ATB-BMPA (50, 100, 200, 300 mM final concentra-
tion) was then added for an additional 10 min (5 min at room
temperature, 5 min at 4
oC).Samples(110 ml final volume) were UV
irradiated as described above. After removal of excess label with a
desalting spin column, GLUT4 protein was immunoprecipitated
from Thesit-solubilized LDM using a GLUT4 C-terminal directed
antibody. ATB-BMPA-bound GLUT4 was analyzed by immuno-
blot analysis using an IR Dye 800 CW fluorescent streptavidin (LI-
COR) and quantified with an Odyssey Infrared Imaging System.
Identical samples that were not UV irradiated were used to correct
for non-specific binding. The free ATB-BMPA concentration was
assumed to be equal to the total ATB-BMPA concentration since
the label concentration far exceeded the GLUT4 concentration.
The data was expressed as Scatchard plots, bound/free versus
bound. The Bmax and Kd values were determined from the
horizontal intercept and the negative of the slope, respectively. The
KI of indinavir was derived from the equation Kd(apparent) = Kd
(1 + [I]/KI) which assumes mutual exclusivity between the two
ligands (indinavir and ATB-BMPA) [20].
Results
Characterization of ATB-BMPA binding
The membrane impermeant bis-mannose containing photolabel
ATB-BMPA, which inhibits sugar uptake in human erythrocytes
and insulin-stimulated rat adipocytes with a Ki,350 mM, has been
used extensively to quantify cell surface levels of GLUT proteins
[21]. ATB-BMPA is generally regarded as an exofacial photolabel
and has been used primarily with intact cells [19,22]. However, if
provided accessibility to the endofacial surface of the transporter,
ATB-BMPA should theoretically be capable of labeling the
cytoplasmic glucose binding site. To test this possibility, ATB-
BMPA was used to photolabel low-density microsomes of 3T3-L1
adipocytes. LDM contains small intracellular vesicles of GLUT4
and GLUT1 that translocate and fuse with the plasma membrane
(PM) in response to insulin resulting in a dramatic increase in
sugar uptake in fat and muscle [23]. In these vesicles, the
transporter orientation is inverted relative to that found in the
plasma membrane. Specifically, the amino and carboxy termini of
GLUT4 and GLUT1 are positioned on the endofacial membrane
surface of intact cell but are exofacially oriented in LDM vesicles.
Greater than 70% of the GLUT4 vesicles could by immuno-
isolated from non-detergent solubilized LDM using a C-terminal
directed GLUT4 antibody demonstrating that the vast majority of
GLUT4 in LDM was found in this membrane orientation
(Fig. 1A). For comparison, using detergent solublized LDM, the
efficiency of immunoprecipitation was greater than 95%. As
predicted, initial experiments revealed that glucose transporters
found in isolated LDM are photolabeled with biotinylated ATB-
BMPA in a LDM concentration dependent and cytochalasin B
(CB) sensitive manner (Fig. 1B). The time course of incubation of
Figure 1. Labeling glucose transporters with biotinylated ATB-
BMPA using low-density microsomes. LDM were isolated from
fully differentiated 3T3-L1 adipocytes as described in ‘‘Materials and
Methods’’. In (A), 175 mg of intact or Thesit-solubilized LDM were
immunoprecipitated overnight with 25 mg of control rabbit IgG or
25 mg of GLUT4 C-terminal antibodies precoupled to Protein A-agarose.
The supernatant (sup) and pellets were analyzed by immunoblot
analysis using a monoclonal GLUT4 antibody (Cell Signaling). In (B),
,1% ethanol (vehicle control) or 20 mM cytochalasin B (CB) were added
to the indicated amount of LDM for 10 min at room temperature.
Samples were then incubated for an additional 10 min in the dark at
room temperature with biotinylated ATB-BMPA (250 mM final concen-
tration). UV irradiation was then performed as described in ‘‘Materials
and Methods’’. Excess photolabel was removed using a spin desalting
column. Membranes were solubilized in 2% Thesit detergent buffer and
biotinylated proteins were isolated using a high capacity streptavidin
agarose resin, and immunoblotted with anti-GLUT4 antibody. GLUT4
protein was quantified using an Odyssey Infrared Imaging System.
Membranes containing biotinylated ATB-BMPA that were not irradiated
with UV are shown for comparison. In (C), biotinylated ATB-BMPA
(50 mM final concentration) was added to 70 mg of LDM for varying
times prior to UV irradiation. Biotinylated proteins were isolated as
described in A, and then analyzed by immunoblot analysis using GLUT4
and GLUT1 antibodies. Glut proteins were quantified using an Odyssey
Infrared Imaging System.
doi:10.1371/journal.pone.0025237.g001
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at steady state between 5 and 25 min (Fig. 1C). Furthermore, CB
reduced ATB-BMPA labeling of LDM in a concentration
dependent manner (Fig. 2). The half maximal concentration of
inhibition (IC50) of CB for ATB-BMPA binding to GLUT4
(0.4460.07 mM) and GLUT1 (0.3560.02 mM), is in agreement
with previously reported CB inhibition of 2-deoxy-glucose uptake
into myotubes (IC50=0.4 mM) [24].
Effect of PIs on ATB-BMPA labeling and glucose uptake
Given the tight correlation between the IC50 values for
photolabel binding to GLUT1 and GLUT4 and glucose transport
inhibition by CB, the ability of HIV protease inhibitors (PIs) to
similarly alter ATB-BMPA labeling and 2-DG uptake was
determined at two different concentrations of PI, 50 mM (Fig. 3)
and 10 mM (Fig4).Photolabeling experimentswerecarried outwith
LDM of 3T3-L1 adipocytes to examine the effect of the PIs on
ATB-BMPA binding to both GLUT4 and GLUT1. Uptake
experiments were conducted in two mammalian cells, 3T3-L1
fibroblasts which are known to express only GLUT1 and in primary
rat adipocytes which predominantly express GLUT4 (.90%).
Previous results [25] along with our current findings (Fig. 3C and
4C) indicate that indinavir is a selective inhibitor of GLUT4
transporter activity when compared to GLUT1. The selectivity of
indinavir for GLUT4 was alsoconfirmed in the ATB-BMPA/LDM
photolabeling experiments (Fig. 3B and 4B). Using a therapeutic
concentration of indinavir (10 mM), both ATB-BMPA binding and
transporter activity were reduced for GLUT4 while GLUT1 was
unaffected (Fig. 4). At a higher indinavir dose (50 mM), GLUT1 was
also affected but a lesser extent than GLUT4 (Fig. 3).
Unlike indinavir, ritonavir was found to be nonselective for
inhibition of both GLUT1 and GLUT4 ATB-BMPA labeling and
glucose uptake at both drug doses studied (Fig. 3 and 4).
Atazanavir was also a non-specific GLUT inhibitor at the
50 mM dose (Fig. 3). At a therapeutic level, however, atazanavir
had no effect on either transporter (Fig. 4). This result is consistent
with published reports that therapeutic doses of atazanavir do not
inhibit glucose uptake in vitro or in vivo [26,27]. Indinavir, ritonavir,
Figure 2. Dose response inhibition of ATB-BMPA photolabeling
by cytochalasin B. A. ATB-BMPA photolabeling. Ethanol (vehicle
control) or cytochalasin B (CB) were added to 200 mg LDM for 10 min
at room temperature. Samples were then irradiated with biotinylated
ATB-BMPA (50 mM final concentration) as described in ‘‘Materials and
Methods’’. Biotinylated proteins, isolated from detergent solubilized
LDM using a high-capacity streptavidin agarose resin, were analyzed by
immunoblot analysis using GLUT4 or GLUT1 antibodies. B. Quantifica-
tion of ATB-BMPA results. GLUT proteins were quantified using an
Odyssey Infrared Imaging System. Data, normalized to vehicle controls,
represent the mean 6 S.E. of three independent experiments. Half
maximal inhibition (IC50) of ATB-BMPA binding to GLUT4 and GLUT1 by
CB were determined using a nonlinear least squares analysis (GraphPad
Prism, v. 5.0).
doi:10.1371/journal.pone.0025237.g002
Figure 3. Inhibition of ATB-BMPA photolabeling and glucose
uptake by 50 mM HIV protease inhibitors. A, ATB-BMPA photola-
beling. Indinavir (Ind), atazanavir (Atz), ritonavir (Rit), and tipranavir (Tip)
(50 mM final concentrations) were added to 200 mg of LDM for 10 min
at room temperature. ATB-BMPA (50 mM final concentration) was then
added for 10 min at room temperature prior to UV irradiation.
Biotinylated proteins were isolated as described in ‘‘Materials and
Methods’’ and then analyzed by immunoblot analysis using GLUT4 and
GLUT1 antibodies. The effect of 20 mM cytochalasin B (CB) and no UV
irradiation are shown for comparison. B, Quantification of ATB-BMPA
results GLUT4 and GLUT1 protein were quantified using an Odyssey
Infrared Imaging System. Data, normalized to vehicle treated controls,
are shown as the mean 6 S.E., n=3; (*), p,0.05 vs. vehicle as
determined by the Student’s t test; (+), p,0.05 for ATB-BMPA/GLUT4 vs.
ATB-BMPA/GLUT1 binding. C. Glucose Uptakes. Indinavir (Ind), atazanavir
(Atz), ritonavir (Rit), and tipranavir (Tip) (50 mM) were added 5–6 min
prior to glucose uptake in insulin-stimulated (1 mM insulin for 20 min)
primary rat adipocytes and basal 3T3-L1 fibroblasts. [
3H]2-Deoxyglucose
uptake was measured at 37uC for 1 min in primary rat adipocytes (open
bar) and for 6 min in basal 3T3-L1 fibroblasts (filled bar). Data shown as
mean uptakes 6 S.E. relative to control, n=4; (*), p,0.05 vs. vehicle; (+),
p,0.05 primary adipocytes vs. basal 3T3-L1 fibroblasts.
doi:10.1371/journal.pone.0025237.g003
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affected GLUT4 and GLUT1 at the 50 mM dosage. Newer PIs
like tipranavir have a non-pepidomimetic structure. Interestingly,
tipranavir had no effect on the GLUT transporters at either
dosage supporting the requirement of peptidomimetic structure for
GLUT binding (Fig. 3 and 4).
Protease inhibitor IC50 values for ATB-BMPA labeling of
GLUT4 and GLUT1
To further characterize the effects of the PIs on ATB-BMPA
photolabeling of GLUT4 and GLUT1, PI dose response
experiments were conducted with indinavir, ritonavir, and
atazanavir. The dose response curves clearly show that indinavir
selectively inhibits GLUT4 at all PI concentrations tested while
ritonavir and atazanavir were non-selective (Fig. 5). IC50 values
were determined from the dose response data using a non-linear
least squares analysis (Table 1). The GLUT4 and GLUT1 IC50
values for indinavir of 20.7 and 178 mM, respectively, is relatively
consistent with the IC50 values for the inhibition of 2-deoxyglucose
uptake by indinavir in primary rat adipocytes (IC50=11mM) and
3T3-L1 fibroblasts (IC50=241 mM). The IC50 values for ritonavir
were ,7 mM for both transporters indicating that ritonavir again
is a non-selective GLUT inhibitor but also more potent than
indinavir. In fact, since ritonavir is poorly soluble in aqueous
solutions, the true IC50 values for ritonavir may actually be lower.
The IC50 values for atazanavir were ,60 mM for both GLUTs
indicating both the non-selective nature of the inhibition and that
atazanavir inhibits GLUT4 less but GLUT1 more than indinavir.
Kinetic analysis of PI effects on ATB-BMPA labeling of
LDM
Due to the presence of two distinct glucose binding sites in
GLUTs on opposite sides of the cell membrane, the binding of PIs
to the cytoplasmic glucose binding domain will appear non-
competitive when zero trans 2DG uptake is measured since the
tracer glucose analog does not have access to this site prior to
facilitative transport. With demonstration that PIs interfere with the
ATB-BMPA labeling of the cytoplasmic glucose binding site, we
next determined the kinetic behavior of this effect. As shown in
Figure 6, indinavir competitively blocks ATB-BMPA binding to
GLUT4 in isolated LDM. The Bmax (horizontal intercept) was
constant while the Kd values (-1/slope) progressively increased with
indinavir concentration. The calculated Kd values were 75, 152,
218, and 510 mM for 0, 10, 20, and 50 mM indinavir, respectively.
The KI of indinavir, calculated as described in ‘‘Materials and
Methods’’ was 8.2 mM. This is somewhat lower than the KI of
15 mM that was previously calculated from inhibition of zero trans
glucose uptake in primary rat adipocytes [28]. The apparent
difference between these values may reflect the influence of PI
permeability and/or transport across the membrane.
Discussion
Efforts to understand the mechanisms for altered glucose
homeostasis in HIV infected patients have been limited by the
complexity of interacting environmental, genetic, treatment and
disease-related factors involved. Nevertheless, it is well established
that antiretroviral therapy directly contributes to the development
of diabetes [4] . Among the various antiretroviral agents in clinical
use, HIV protease inhibitors are known to influence peripheral
glucose disposal, hepatic glucose production, and insulin secretion
[29]. Contrary to the initial speculation that induction of insulin
resistance is a shared feature of all PIs, subsequent investigation
has shown that individual agents within this drug class have
differing effects on glucose homeostasis, both in vitro and in treated
patients. The initial identification and characterization of GLUT4
as a direct molecular target of PIs was performed using indinavir
[25]. The isoform selectivity of this drug (i.e. the ability to block
GLUT4 activity with no effect on GLUT1) was established in
Xenopus oocytes heterologously expressing either of these glucose
transporters [28]. While it has been generally assumed that all PIs
possess the same degree of isoform selectivity as indinavir, direct
comparisons of glucose transport blockade in GLUT1 versus
GLUT4 expressing cells have been lacking. The binding affinity
(KI) of indinavir for GLUT4 in the oocyte system (50 mM) differs
from that observed in primary adipocytes (15 mM). While the basis
for this difference is unknown, contributing factors may include
Figure 4. Inhibition of ATB-BMPA photolabeling and glucose
uptake by 10 mM HIV protease inhibitors. A, ATB-BMPA photola-
beling. Indinavir (Ind), atazanavir (Atz), ritonavir (Rit), and tipranavir (Tip)
(10 mM final concentrations) were added to 200 mg of LDM for 10 min
at room temperature. ATB-BMPA (50 mM final concentration) was then
added for 10 min at room temperature prior to UV irradiation.
Biotinylated proteins were isolated as described in ‘‘Materials and
Methods’’ and then analyzed by immunoblot analysis using GLUT4 and
GLUT1 antibodies. B, Quantification of ATB-BMPA results GLUT4 and
GLUT1 protein were quantified using an Odyssey Infrared Imaging
System. Data, normalized to vehicle treated controls, are shown as the
mean 6 S.E., n=3; (*), p,0.05 vs. vehicle as determined by the
Student’s t test; (+), p,0.05 for ATB-BMPA/GLUT4 vs. ATB-BMPA/GLUT1
binding. C. Glucose Uptakes. Indinavir (Ind), atazanavir (Atz), ritonavir
(Rit), and tipranavir (Tip) (10 mM) were added 5–6 min prior to glucose
uptakes in insulin-stimulated (1 mM insulin for 20 min) primary rat
adipocytes and basal 3T3-L1 fibroblasts. [
3H]2-Deoxyglucose uptake
was measured at 37uC for 1 min in primary rat adipocytes (open bar)
and for 6 min in basal 3T3-L1 fibroblasts (filled bar). Data shown as
mean uptakes 6 S.E. relative to control, n=4; (*), p,0.05 vs. vehicle, (+),
p,0.05 primary adipocytes vs. basal 3T3-L1 fibroblasts.
doi:10.1371/journal.pone.0025237.g004
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lipid composition, assay temperature, the presence of additional
proteins, or other factors. It was therefore necessary to directly
compare the ability of both first generation and newer PIs to alter
GLUT1 versus GLUT4 activity. These data provide a more
comprehensive assessment of similarities and differences in the
behavior of these PIs on facilitative glucose transport.
Several observations related to the ability of PIs examined in
this study to compete for endofacial ATB BMPA binding have
direct relevance to understanding the metabolic toxicities of these
drugs in antiretroviral treatment regimens. Importantly, few
studies to date have directly assessed the relationship between
intracellular PI concentrations and impaired glucose uptake.
Whether PI import occurs via simple diffusion or through
mediated transport, sufficient drug levels may be present within
the cytosol even when serum levels are low [30]. In addition, while
it has been assumed that all PIs possess the same degree of GLUT
isoform selectivity as indinavir, several PIs including ritonavir do
not appear to distinguish among these transporters. Thus, the
effects of some PIs on glucose homeostasis in tissues that do not
express GLUT4 (such as hepatic glucose production in the liver
and glucose-stimulated insulin secretion from b-cells) may still be
mediated by changes in glucose transport. Comparison of the
effects of various PIs in these tissues may provide further insight
into the mechanistic basis for altered glucose homeostasis. More
comprehensive assessment of the ability of individual PIs to block
each of the other known GLUTs may provide insight into
glucotoxicities. While atazanavir has a more favorable metabolic
profile relative to first generation PIs, the current studies
demonstrate that at drug levels above those typically achieved
during clinical use, the potential for significantly altering glucose
transport exists. The inability of tipranavir to alter either ATB
BMPA binding or 2DG transport further supports the role of
peptidomimetic structure in mediating binding to GLUTs.
Understanding of the molecular basis for the development of
insulin resistance in HIV infected patients treated with PIs has
already contributed to success in developing drugs within this class
that do not directly alter glucose homeostasis. Nevertheless, many
of these newer agents including tipranavir are associated with
Figure 5. Indinavir but not ritonavir or atazanavir selectively
inhibits ATB-BMPA binding to GLUT4 relative to that of GLUT1.
Indinavir, ritonavir, and atazanavir were added to 200 mg of LDM for
10 min at room temperature. ATB-BMPA (50 mM final concentration)
was then added for 10 min at room temperature prior to UV irradiation.
Biotinylated proteins were isolated as described in ‘‘Materials and
Methods’’ and then analyzed by immunoblot analysis using GLUT4 and
GLUT1 antibodies. GLUT4 and GLUT1 protein were quantified using an
Odyssey Infrared Imaging System. Data, normalized to vehicle treated
controls, are shown as the mean 6 S.E., n=3; (*), p,0.05 for ATB-BMPA/
GLUT4 vs. ATB-BMPA/GLUT1 binding as determined by the Student’s t
test.
doi:10.1371/journal.pone.0025237.g005
Table 1. Half-maximal inhibition (IC50) for ATB-BMPA binding
to GLUT4 and GLUT1 by PI’s.
GLUT4 GLUT1
Indinavir 20.763.9 mM 178643 mM*
Ritonavir 7.061.1 mM 7.960.4 mM
Atazanavir 6663.3 mM5 9 64.8 mM
IC50 values were determined from the dose response data (Fig. 5) using a
nonlinear least squares analysis (GraphPad Prism, v. 5.0). (*), p,0.05 for IC50
values for ATB-BMPA binding to GLUT4 vs. GLUT1 as determined by the
Student’s t test.
doi:10.1371/journal.pone.0025237.t001
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impaired insulin signaling. Furthermore, with the potential for
development of viral resistance over time, the need for continued
drug development remains. Characterization of the molecular
interactions between candidate drugs and GLUTs will assist
ongoing efforts for rationale drug design, not only for antiviral
efficacy, but also for metabolic toxicity.
Beyond further understanding of the mechanisms for PI-
mediated insulin resistance, the ability to distinguish compounds
that selectively interact with GLUT4 from those that bind to both
GLUT1 and GLUT4 suggests that it may be possible to identify
small molecule inhibitors of each of the other known GLUTs [32].
The availability of specific pharmacologic inhibitors of these
transporters would provide a means to further characterize the
functional role of these isoforms prior to the induction of potential
compensatory changes in gene knockout models.
The development and use of an ATB-BMPA based assay for
labeling of the cytoplasmic glucose binding site of GLUTs provides
potential uses for this agent that extends its traditional use to
quantify cell surface levels of GLUTs. This includes elucidation of
the functional significance of cytosolic binding of known GLUT-
interacting proteins and the discovery of additional protein-protein
interactions. Such applications may aid efforts to identify means to
improve diabetes treatment in the wider context of non-HIV
associated insulin resistance.
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